메뉴 건너뛰기




Volumn 6, Issue , 2013, Pages 1079-1095

Combining molecular targeted agents with radiation therapy for malignant gliomas

Author keywords

Glioblastoma; High grade glioma; Radiation therapy; Targeted therapy; Temozolomide

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CEDIRANIB; CETUXIMAB; CILENGITIDE; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; LAPATINIB; PLACEBO; RAPAMYCIN; RIDAFOROLIMUS; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TORISE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VATALANIB;

EID: 84881390190     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S48224     Document Type: Review
Times cited : (28)

References (164)
  • 1
    • 33747195058 scopus 로고    scopus 로고
    • Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemi-ology, and End Results Program, 1973 to 2001
    • Deorah S, Lynch CF, Sibenaller ZA, Ryken TC. Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemi-ology, and End Results Program, 1973 to 2001. Neurosurg Focus. 2006;20(4):E1.
    • (2006) Neurosurg Focus , vol.20 , Issue.4
    • Deorah, S.1    Lynch, C.F.2    Sibenaller, Z.A.3    Ryken, T.C.4
  • 2
    • 20044366163 scopus 로고    scopus 로고
    • European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
    • Stupp R, Mason WP, van den Bent MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
    • (2005) N Engl J Med , vol.352 , Issue.10 , pp. 987-996
    • Stupp, R.1    Mason, W.P.2    van den Bent, M.J.3
  • 3
    • 77953617053 scopus 로고    scopus 로고
    • Phase II trial of erlotinib with temozolomide and radiation in patients with newly diag-nosed glioblastoma multiforme
    • Peereboom DM, Shepard DR, Ahluwalia MS, et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diag-nosed glioblastoma multiforme. J Neurooncol. 2010;98(1):93-99.
    • (2010) J Neurooncol , vol.98 , Issue.1 , pp. 93-99
    • Peereboom, D.M.1    Shepard, D.R.2    Ahluwalia, M.S.3
  • 4
    • 59149086517 scopus 로고    scopus 로고
    • Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma
    • Prados MD, Chang SM, Butowski N, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009;27(4):579-584.
    • (2009) J Clin Oncol , vol.27 , Issue.4 , pp. 579-584
    • Prados, M.D.1    Chang, S.M.2    Butowski, N.3
  • 5
    • 79955582712 scopus 로고    scopus 로고
    • Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074
    • Uhm JH, Ballman KV, Wu W, et al. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int J Radiat Oncol Biol Phys. 2011;80(2):347-353.
    • (2011) Int J Radiat Oncol Biol Phys , vol.80 , Issue.2 , pp. 347-353
    • Uhm, J.H.1    Ballman, K.V.2    Wu, W.3
  • 6
    • 34247218483 scopus 로고    scopus 로고
    • Gefitinib in patients with progressive high-grade gliomas: A multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
    • Franceschi E, Cavallo G, Lonardi S, et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer. 2007;96(7):1047-1051.
    • (2007) Br J Cancer , vol.96 , Issue.7 , pp. 1047-1051
    • Franceschi, E.1    Cavallo, G.2    Lonardi, S.3
  • 7
    • 84856271656 scopus 로고    scopus 로고
    • New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium. Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma
    • Nabors LB, Supko JG, Rosenfeld M, et al; New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium. Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. Neuro-oncology. 2011;13(12):1324-1330.
    • (2011) Neuro-oncology , vol.13 , Issue.12 , pp. 1324-1330
    • Nabors, L.B.1    Supko, J.G.2    Rosenfeld, M.3
  • 8
    • 83955164336 scopus 로고    scopus 로고
    • Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas
    • Fields EC, Damek D, Gaspar LE, et al. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2012;82(1):51-57.
    • (2012) Int J Radiat Oncol Biol Phys , vol.82 , Issue.1 , pp. 51-57
    • Fields, E.C.1    Damek, D.2    Gaspar, L.E.3
  • 9
    • 79959841782 scopus 로고    scopus 로고
    • Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glio-blastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide
    • Gerstner ER, Eichler AF, Plotkin SR, et al. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glio-blastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol. 2011;103(2):325-332.
    • (2011) J Neurooncol , vol.103 , Issue.2 , pp. 325-332
    • Gerstner, E.R.1    Eichler, A.F.2    Plotkin, S.R.3
  • 10
    • 79959213028 scopus 로고    scopus 로고
    • The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma
    • Vredenburgh JJ, Desjardins A, Reardon DA, et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res. 2011;17(12):4119-4124.
    • (2011) Clin Cancer Res , vol.17 , Issue.12 , pp. 4119-4124
    • Vredenburgh, J.J.1    Desjardins, A.2    Reardon, D.A.3
  • 11
    • 79951984402 scopus 로고    scopus 로고
    • Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme
    • Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29(2): 142-148.
    • (2011) J Clin Oncol , vol.29 , Issue.2 , pp. 142-148
    • Lai, A.1    Tran, A.2    Nghiemphu, P.L.3
  • 12
    • 23944453425 scopus 로고    scopus 로고
    • North Central Cancer Treatment Group. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study
    • Galanis E, Buckner JC, Maurer MJ, et al; North Central Cancer Treatment Group. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005;23(23):5294-5304.
    • (2005) J Clin Oncol , vol.23 , Issue.23 , pp. 5294-5304
    • Galanis, E.1    Buckner, J.C.2    Maurer, M.J.3
  • 13
    • 77954924659 scopus 로고    scopus 로고
    • Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma
    • Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(16):2712-2718.
    • (2010) J Clin Oncol , vol.28 , Issue.16 , pp. 2712-2718
    • Stupp, R.1    Hegi, M.E.2    Neyns, B.3
  • 14
    • 84868193304 scopus 로고    scopus 로고
    • New Approaches to Brain Tumor Therapy (NABTT) Central Nervous System Consortium. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)
    • Nabors LB, Mikkelsen T, Hegi ME, et al; New Approaches to Brain Tumor Therapy (NABTT) Central Nervous System Consortium. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer. 2012;118(22):5601-5607.
    • (2012) Cancer , vol.118 , Issue.22 , pp. 5601-5607
    • Nabors, L.B.1    Mikkelsen, T.2    Hegi, M.E.3
  • 15
    • 75149186046 scopus 로고    scopus 로고
    • Chemotherapy for glioblastoma: Current treatment and future perspectives for cytotoxic and targeted agents
    • Minniti G, Muni R, Lanzetta G, et al; chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res. 2009;29(12):5171-5184.
    • (2009) Anticancer Res , vol.29 , Issue.12 , pp. 5171-5184
    • Minniti, G.1    Muni, R.2    Lanzetta, G.3
  • 16
    • 84878846850 scopus 로고    scopus 로고
    • Promising new molecular targeted therapies in head and neck cancer
    • Dorsey K, Agulnik M. Promising new molecular targeted therapies in head and neck cancer. Drugs. 2013;73(4):315-325.
    • (2013) Drugs , vol.73 , Issue.4 , pp. 315-325
    • Dorsey, K.1    Agulnik, M.2
  • 18
    • 0033564974 scopus 로고    scopus 로고
    • Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation
    • Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999;59(14):3374-3378.
    • (1999) Cancer Res , vol.59 , Issue.14 , pp. 3374-3378
    • Gorski, D.H.1    Beckett, M.A.2    Jaskowiak, N.T.3
  • 19
    • 0035866771 scopus 로고    scopus 로고
    • Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy
    • Geng L, Donnelly E, McMahon G, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 2001;61(6):2413-2419.
    • (2001) Cancer Res , vol.61 , Issue.6 , pp. 2413-2419
    • Geng, L.1    Donnelly, E.2    McMahon, G.3
  • 20
    • 0036371621 scopus 로고    scopus 로고
    • Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance
    • Gupta VK, Jaskowiak NT, Beckett MA, et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J. 2002;8(1):47-54.
    • (2002) Cancer J , vol.8 , Issue.1 , pp. 47-54
    • Gupta, V.K.1    Jaskowiak, N.T.2    Beckett, M.A.3
  • 21
    • 26944487557 scopus 로고    scopus 로고
    • Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multi-forme cell lines - a clue to radioresistance?
    • Hovinga KE, Stalpers LJ, van Bree C, et al. Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multi-forme cell lines - a clue to radioresistance? J Neurooncol. 2005;74(2): 99-103.
    • (2005) J Neurooncol , vol.74 , Issue.2 , pp. 99-103
    • Hovinga, K.E.1    Stalpers, L.J.2    van Bree, C.3
  • 22
    • 33947531672 scopus 로고    scopus 로고
    • VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma
    • Wachsberger PR, Burd R, Cardi C, et al. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys. 2007;67(5):1526-1537.
    • (2007) Int J Radiat Oncol Biol Phys , vol.67 , Issue.5 , pp. 1526-1537
    • Wachsberger, P.R.1    Burd, R.2    Cardi, C.3
  • 23
    • 84858442412 scopus 로고    scopus 로고
    • Post-radiation increase in VEGF enhances glioma cell motility in vitro
    • Kil WJ, Tofilon PJ, Camphausen K. Post-radiation increase in VEGF enhances glioma cell motility in vitro. Radiat Oncol. 2012;7:25.
    • (2012) Radiat Oncol , vol.7 , pp. 25
    • Kil, W.J.1    Tofilon, P.J.2    Camphausen, K.3
  • 24
    • 0344837730 scopus 로고    scopus 로고
    • Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: Evidence for distinct angiogenic subtypes
    • Birner P, Piribauer M, Fischer I, et al. Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol. 2003;13(2):133-143.
    • (2003) Brain Pathol , vol.13 , Issue.2 , pp. 133-143
    • Birner, P.1    Piribauer, M.2    Fischer, I.3
  • 25
    • 0030856731 scopus 로고    scopus 로고
    • Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
    • Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20): 4593-4599.
    • (1997) Cancer Res , vol.57 , Issue.20 , pp. 4593-4599
    • Presta, L.G.1    Chen, H.2    O'Connor, S.J.3
  • 26
    • 13444278498 scopus 로고    scopus 로고
    • Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies
    • Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005;65(3):671-680.
    • (2005) Cancer Res , vol.65 , Issue.3 , pp. 671-680
    • Gerber, H.P.1    Ferrara, N.2
  • 27
    • 0029949160 scopus 로고    scopus 로고
    • Time-dependent vascular regression and permeability changes in estab-lished human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody
    • Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in estab-lished human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A. 1996;93(25):14765-14770.
    • (1996) Proc Natl Acad Sci U S A , vol.93 , Issue.25 , pp. 14765-14770
    • Yuan, F.1    Chen, Y.2    Dellian, M.3    Safabakhsh, N.4    Ferrara, N.5    Jain, R.K.6
  • 28
    • 0029816983 scopus 로고    scopus 로고
    • Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothe-lial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy
    • Borgström P, Hillan KJ, Sriramarao P, Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothe-lial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 1996;56(17): 4032-4039.
    • (1996) Cancer Res , vol.56 , Issue.17 , pp. 4032-4039
    • Borgström, P.1    Hillan, K.J.2    Sriramarao, P.3    Ferrara, N.4
  • 29
    • 11144354392 scopus 로고    scopus 로고
    • Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
    • Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10(2):145-147.
    • (2004) Nat Med , vol.10 , Issue.2 , pp. 145-147
    • Willett, C.G.1    Boucher, Y.2    di Tomaso, E.3
  • 30
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus iri-notecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus iri-notecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
    • (2004) N Engl J Med , vol.350 , Issue.23 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3
  • 31
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    • Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-2550.
    • (2006) N Engl J Med , vol.355 , Issue.24 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3
  • 32
    • 37349080670 scopus 로고    scopus 로고
    • AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial
    • Escudier B, Pluzanska A, Koralewski P, et al; AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103-2111.
    • (2007) Lancet , vol.370 , Issue.9605 , pp. 2103-2111
    • Escudier, B.1    Pluzanska, A.2    Koralewski, P.3
  • 33
    • 70350461699 scopus 로고    scopus 로고
    • Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
    • Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
    • (2009) J Clin Oncol , vol.27 , Issue.28 , pp. 4733-4740
    • Friedman, H.S.1    Prados, M.D.2    Wen, P.Y.3
  • 34
    • 59949083263 scopus 로고    scopus 로고
    • Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
    • Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5): 740-745.
    • (2009) J Clin Oncol , vol.27 , Issue.5 , pp. 740-745
    • Kreisl, T.N.1    Kim, L.2    Moore, K.3
  • 35
    • 19944422751 scopus 로고    scopus 로고
    • Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases
    • Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6(6):553-563.
    • (2004) Cancer Cell , vol.6 , Issue.6 , pp. 553-563
    • Winkler, F.1    Kozin, S.V.2    Tong, R.T.3
  • 37
    • 0034306974 scopus 로고    scopus 로고
    • Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions
    • Lee CG, Heijn M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000;60(19):5565-5570.
    • (2000) Cancer Res , vol.60 , Issue.19 , pp. 5565-5570
    • Lee, C.G.1    Heijn, M.2    di Tomaso, E.3
  • 38
    • 34250660932 scopus 로고    scopus 로고
    • Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization
    • Dings RP, Loren M, Heun H, et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res. 2007;13(11):3395-3402.
    • (2007) Clin Cancer Res , vol.13 , Issue.11 , pp. 3395-3402
    • Dings, R.P.1    Loren, M.2    Heun, H.3
  • 39
    • 77949553030 scopus 로고    scopus 로고
    • Improved intratumoral oxygenation through vascular normalization increases glioma sensi-tivity to ionizing radiation
    • McGee MC, Hamner JB, Williams RF, et al. Improved intratumoral oxygenation through vascular normalization increases glioma sensi-tivity to ionizing radiation. Int J Radiat Oncol Biol Phys. 2010;76(5): 1537-1545.
    • (2010) Int J Radiat Oncol Biol Phys , vol.76 , Issue.5 , pp. 1537-1545
    • McGee, M.C.1    Hamner, J.B.2    Williams, R.F.3
  • 40
    • 51449116659 scopus 로고    scopus 로고
    • Feasibility of using bevaci-zumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma
    • Narayana A, Golfinos JG, Fischer I, et al. Feasibility of using bevaci-zumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys. 2008;72(2): 383-389.
    • (2008) Int J Radiat Oncol Biol Phys , vol.72 , Issue.2 , pp. 383-389
    • Narayana, A.1    Golfinos, J.G.2    Fischer, I.3
  • 41
    • 84856806386 scopus 로고    scopus 로고
    • A clinical trial of bevaci-zumab, temozolomide, and radiation for newly diagnosed glioblastoma
    • Narayana A, Gruber D, Kunnakkat S, et al. A clinical trial of bevaci-zumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg. 2012;116(2):341-345.
    • (2012) J Neurosurg , vol.116 , Issue.2 , pp. 341-345
    • Narayana, A.1    Gruber, D.2    Kunnakkat, S.3
  • 42
    • 45249097586 scopus 로고    scopus 로고
    • Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: Interim analysis of safety and tolerability
    • Lai A, Filka E, McGibbon B, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys. 2008;71(5):1372-1380.
    • (2008) Int J Radiat Oncol Biol Phys , vol.71 , Issue.5 , pp. 1372-1380
    • Lai, A.1    Filka, E.2    McGibbon, B.3
  • 43
    • 83955165997 scopus 로고    scopus 로고
    • Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme
    • Vredenburgh JJ, Desjardins A, Kirkpatrick JP, et al. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2012;82(1):58-66.
    • (2012) Int J Radiat Oncol Biol Phys , vol.82 , Issue.1 , pp. 58-66
    • Vredenburgh, J.J.1    Desjardins, A.2    Kirkpatrick, J.P.3
  • 44
    • 84859628071 scopus 로고    scopus 로고
    • Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma
    • Hainsworth JD, Shih KC, Shepard GC, Tillinghast GW, Brinker BT, Spigel DR. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. Clin Adv Hematol Oncol. 2012;10(4):240-246.
    • (2012) Clin Adv Hematol Oncol , vol.10 , Issue.4 , pp. 240-246
    • Hainsworth, J.D.1    Shih, K.C.2    Shepard, G.C.3    Tillinghast, G.W.4    Brinker, B.T.5    Spigel, D.R.6
  • 45
    • 79958210803 scopus 로고    scopus 로고
    • AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
    • Chinot OL, de La Motte Rouge T, Moore N et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther. 2011;28(4):334-340.
    • (2011) Adv Ther , vol.28 , Issue.4 , pp. 334-340
    • Chinot, O.L.1    de La Motte Rouge, T.2    Moore, N.3
  • 46
    • 68649114787 scopus 로고    scopus 로고
    • Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas
    • Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009;75(1):156-163.
    • (2009) Int J Radiat Oncol Biol Phys , vol.75 , Issue.1 , pp. 156-163
    • Gutin, P.H.1    Iwamoto, F.M.2    Beal, K.3
  • 47
    • 84873293197 scopus 로고    scopus 로고
    • Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma
    • Shapiro LQ, Beal K, Goenka A, et al. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma. Int J Radiat Oncol Biol Phys. 2013;85(3):636-642.
    • (2013) Int J Radiat Oncol Biol Phys , vol.85 , Issue.3 , pp. 636-642
    • Shapiro, L.Q.1    Beal, K.2    Goenka, A.3
  • 48
    • 83955166003 scopus 로고    scopus 로고
    • Irradiation and bevacizumab in high-grade glioma retreatment settings
    • Niyazi M, Ganswindt U, Schwarz SB, et al. Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys. 2012;82(1):67-76.
    • (2012) Int J Radiat Oncol Biol Phys , vol.82 , Issue.1 , pp. 67-76
    • Niyazi, M.1    Ganswindt, U.2    Schwarz, S.B.3
  • 49
    • 84874655851 scopus 로고    scopus 로고
    • Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas
    • Hundsberger T, Brügge D, Putora PM, Weder P, Weber J, Plasswilm L. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. J Neurooncol. 2013;112(1):133-139.
    • (2013) J Neurooncol , vol.112 , Issue.1 , pp. 133-139
    • Hundsberger, T.1    Brügge, D.2    Putora, P.M.3    Weder, P.4    Weber, J.5    Plasswilm, L.6
  • 50
    • 0037075812 scopus 로고    scopus 로고
    • Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors
    • Hennequin LF, Stokes ES, Thomas AP, et al. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem. 2002;45(6):1300-1312.
    • (2002) J Med Chem , vol.45 , Issue.6 , pp. 1300-1312
    • Hennequin, L.F.1    Stokes, E.S.2    Thomas, A.P.3
  • 51
    • 0037386774 scopus 로고    scopus 로고
    • Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase
    • Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res. 2003;9(4):1546-1556.
    • (2003) Clin Cancer Res , vol.9 , Issue.4 , pp. 1546-1556
    • Ciardiello, F.1    Caputo, R.2    Damiano, V.3
  • 52
    • 79956051199 scopus 로고    scopus 로고
    • Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in pre-clinical models of human cancer
    • Brave SR, Odedra R, James NH, et al. Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in pre-clinical models of human cancer. Int J Oncol. 2011;39(1):271-278.
    • (2011) Int J Oncol , vol.39 , Issue.1 , pp. 271-278
    • Brave, S.R.1    Odedra, R.2    James, N.H.3
  • 53
    • 84865552505 scopus 로고    scopus 로고
    • Vandetanib in locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 2 trial
    • Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13(9):897-905.
    • (2012) Lancet Oncol , vol.13 , Issue.9 , pp. 897-905
    • Leboulleux, S.1    Bastholt, L.2    Krause, T.3
  • 54
    • 84862184774 scopus 로고    scopus 로고
    • Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer
    • Meyerhardt JA, Ancukiewicz M, Abrams TA, et al. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One. 2012;7(6):e38231.
    • (2012) PLoS One , vol.7 , Issue.6
    • Meyerhardt, J.A.1    Ancukiewicz, M.2    Abrams, T.A.3
  • 55
    • 84861720010 scopus 로고    scopus 로고
    • Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: A random-ized, double-blind phase III trial (ZEPHYR)
    • Lee JS, Hirsh V, Park K, et al. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a random-ized, double-blind phase III trial (ZEPHYR). J Clin Oncol. 2012;30(10): 1114-1121.
    • (2012) J Clin Oncol , vol.30 , Issue.10 , pp. 1114-1121
    • Lee, J.S.1    Hirsh, V.2    Park, K.3
  • 56
    • 84862832278 scopus 로고    scopus 로고
    • Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
    • Hsu C, Yang TS, Huo TI, et al. Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study. J Hepatol. 2012;56(5):1097-1103.
    • (2012) J Hepatol , vol.56 , Issue.5 , pp. 1097-1103
    • Hsu, C.1    Yang, T.S.2    Huo, T.I.3
  • 57
    • 84863890768 scopus 로고    scopus 로고
    • Vandetanib for the treatment of sympomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S
    • Thornton K, Kim G, Maher ve, et al. Vandetanib for the treatment of sympomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug administration drug approval cemicar cancer Res. 2012; 18(14):3722-3730.
    • (2012) Food and Drug Administration Drug Approval Cemicar Cancer Res , vol.18 , Issue.14 , pp. 3722-3730
    • Thornton, K.1    Kim, G.2    Ve, M.3
  • 58
    • 70449704420 scopus 로고    scopus 로고
    • Decrease in tumor cell oxygen consumption after treatment with vande-tanib (ZACTIMA; ZD6474) and its effect on response to radiotherapy
    • Ansiaux R, Dewever J, Grégoire V, Feron O, Jordan BF, Gallez B. Decrease in tumor cell oxygen consumption after treatment with vande-tanib (ZACTIMA; ZD6474) and its effect on response to radiotherapy. Radiat Res. 2009;172(5):584-591.
    • (2009) Radiat Res , vol.172 , Issue.5 , pp. 584-591
    • Ansiaux, R.1    Dewever, J.2    Grégoire, V.3    Feron, O.4    Jordan, B.F.5    Gallez, B.6
  • 59
    • 23044500424 scopus 로고    scopus 로고
    • Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma
    • Damiano V, Melisi D, Bianco C, et al. Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res. 2005;11(15):5639-5644.
    • (2005) Clin Cancer Res , vol.11 , Issue.15 , pp. 5639-5644
    • Damiano, V.1    Melisi, D.2    Bianco, C.3
  • 60
    • 38349085651 scopus 로고    scopus 로고
    • Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model
    • Sandström M, Johansson M, Bergström P, Bergenheim AT, Henriksson R. Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. J Neurooncol. 2008;88(1):1-9.
    • (2008) J Neurooncol , vol.88 , Issue.1 , pp. 1-9
    • Sandström, M.1    Johansson, M.2    Bergström, P.3    Bergenheim, A.T.4    Henriksson, R.5
  • 61
    • 36348941014 scopus 로고    scopus 로고
    • Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts
    • Gustafson DL, Frederick B, Merz AL, Raben D. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. Cancer Chemother Pharmacol. 2008;61(2):179-188.
    • (2008) Cancer Chemother Pharmacol , vol.61 , Issue.2 , pp. 179-188
    • Gustafson, D.L.1    Frederick, B.2    Merz, A.L.3    Raben, D.4
  • 62
    • 11144223542 scopus 로고    scopus 로고
    • ZD6474, a potent inhibitor of vas-cular endothelial growth factor signaling, combined with radiotherapy: Schedule-dependent enhancement of antitumor activity
    • Williams KJ, Telfer BA, Brave S, et al. ZD6474, a potent inhibitor of vas-cular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res. 2004;10(24):8587-8593.
    • (2004) Clin Cancer Res , vol.10 , Issue.24 , pp. 8587-8593
    • Williams, K.J.1    Telfer, B.A.2    Brave, S.3
  • 63
    • 1842689545 scopus 로고    scopus 로고
    • Targeting the tumor vasculature: A strategy to improve radiation therapy
    • Siemann DW, Horsman MR. Targeting the tumor vasculature: a strategy to improve radiation therapy. Expert Rev Anticancer Ther. 2004;4(2):321-327.
    • (2004) Expert Rev Anticancer Ther , vol.4 , Issue.2 , pp. 321-327
    • Siemann, D.W.1    Horsman, M.R.2
  • 64
    • 33646915238 scopus 로고    scopus 로고
    • VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy
    • Brazelle WD, Shi W, Siemann DW. VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy. Int J Radiat Oncol Biol Phys. 2006;65(3):836-841.
    • (2006) Int J Radiat Oncol Biol Phys , vol.65 , Issue.3 , pp. 836-841
    • Brazelle, W.D.1    Shi, W.2    Siemann, D.W.3
  • 65
    • 77955922743 scopus 로고    scopus 로고
    • Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma
    • Drappatz J, Norden AD, Wong ET, et al. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2010;78(1):85-90.
    • (2010) Int J Radiat Oncol Biol Phys , vol.78 , Issue.1 , pp. 85-90
    • Drappatz, J.1    Norden, A.D.2    Wong, E.T.3
  • 66
    • 78149258374 scopus 로고    scopus 로고
    • Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma
    • Broniscer A, Baker JN, Tagen M, et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol. 2010;28(31):4762-4768.
    • (2010) J Clin Oncol , vol.28 , Issue.31 , pp. 4762-4768
    • Broniscer, A.1    Baker, J.N.2    Tagen, M.3
  • 67
    • 0034655182 scopus 로고    scopus 로고
    • PTK787/ZK222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
    • Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000;60(8):2178-2189.
    • (2000) Cancer Res , vol.60 , Issue.8 , pp. 2178-2189
    • Wood, J.M.1    Bold, G.2    Buchdunger, E.3
  • 68
    • 1442290142 scopus 로고    scopus 로고
    • Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms
    • Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004;18(2):338-340.
    • (2004) FASEB J , vol.18 , Issue.2 , pp. 338-340
    • Erber, R.1    Thurnher, A.2    Katsen, A.D.3
  • 69
    • 36249021985 scopus 로고    scopus 로고
    • Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling
    • Hasumi Y, Kłosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer. 2007;121(12):2606-2614.
    • (2007) Int J Cancer , vol.121 , Issue.12 , pp. 2606-2614
    • Hasumi, Y.1    Kłosowska-Wardega, A.2    Furuhashi, M.3    Ostman, A.4    Heldin, C.H.5    Hellberg, C.6
  • 70
    • 0035555907 scopus 로고    scopus 로고
    • Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth
    • Hess C, Vuong V, Hegyi I, et al. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer. 2001;85(12):2010-2016.
    • (2001) Br J Cancer , vol.85 , Issue.12 , pp. 2010-2016
    • Hess, C.1    Vuong, V.2    Hegyi, I.3
  • 71
    • 10744223116 scopus 로고    scopus 로고
    • Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ ZK222584 and fractionated irradiation
    • Zips D, Krause M, Hessel F, et al. Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ ZK222584 and fractionated irradiation. Anticancer Res. 2003;23(5A): 3869-3876.
    • (2003) Anticancer Res , vol.23 , Issue.5 A , pp. 3869-3876
    • Zips, D.1    Krause, M.2    Hessel, F.3
  • 72
    • 20444435955 scopus 로고    scopus 로고
    • Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition
    • Zips D, Eicheler W, Geyer P, et al. Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. Cancer Res. 2005;65(12):5374-5379.
    • (2005) Cancer Res , vol.65 , Issue.12 , pp. 5374-5379
    • Zips, D.1    Eicheler, W.2    Geyer, P.3
  • 73
    • 72449155176 scopus 로고    scopus 로고
    • EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radio-therapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma
    • Brandes AA, Stupp R, Hau P, et al. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radio-therapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer. 2010;46(2):348-354.
    • (2010) Eur J Cancer , vol.46 , Issue.2 , pp. 348-354
    • Brandes, A.A.1    Stupp, R.2    Hau, P.3
  • 74
    • 79956334386 scopus 로고    scopus 로고
    • Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma
    • Hecht JR, Trarbach T, Hainsworth JD, et al. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol. 2011;29(15):1997-2003.
    • (2011) J Clin Oncol , vol.29 , Issue.15 , pp. 1997-2003
    • Hecht, J.R.1    Trarbach, T.2    Hainsworth, J.D.3
  • 75
    • 79956297102 scopus 로고    scopus 로고
    • Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK222584 in patients with previously treated metastatic colorectal adenocarcinoma
    • Van Cutsem E, Bajetta E, Valle J, et al. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol. 2011;29(15):2004-2010.
    • (2011) J Clin Oncol , vol.29 , Issue.15 , pp. 2004-2010
    • van Cutsem, E.1    Bajetta, E.2    Valle, J.3
  • 76
    • 33744513575 scopus 로고    scopus 로고
    • Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK path-way in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature
    • Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK path-way in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Meth Enzymol. 2006;407:597-612.
    • (2006) Meth Enzymol , vol.407 , pp. 597-612
    • Adnane, L.1    Trail, P.A.2    Taylor, I.3    Wilhelm, S.M.4
  • 77
    • 55749088393 scopus 로고    scopus 로고
    • Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
    • Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7(10):3129-3140.
    • (2008) Mol Cancer Ther , vol.7 , Issue.10 , pp. 3129-3140
    • Wilhelm, S.M.1    Adnane, L.2    Newell, P.3    Villanueva, A.4    Llovet, J.M.5    Lynch, M.6
  • 78
    • 47949116252 scopus 로고    scopus 로고
    • SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma
    • Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390.
    • (2008) N Engl J Med , vol.359 , Issue.4 , pp. 378-390
    • Llovet, J.M.1    Ricci, S.2    Mazzaferro, V.3
  • 79
    • 33846148701 scopus 로고    scopus 로고
    • TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma
    • Escudier B, Eisen T, Stadler WM, et al; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-134.
    • (2007) N Engl J Med , vol.356 , Issue.2 , pp. 125-134
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 81
    • 77950833182 scopus 로고    scopus 로고
    • Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3
    • Yang F, Brown C, Buettner R, et al. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Mol Cancer Ther. 2010;9(4):953-962.
    • (2010) Mol Cancer Ther , vol.9 , Issue.4 , pp. 953-962
    • Yang, F.1    Brown, C.2    Buettner, R.3
  • 82
    • 84875522870 scopus 로고    scopus 로고
    • Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures
    • Carra E, Barbieri F, Marubbi D, et al. Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. Cell Cycle. 2013;12(3):491-500.
    • (2013) Cell Cycle , vol.12 , Issue.3 , pp. 491-500
    • Carra, E.1    Barbieri, F.2    Marubbi, D.3
  • 83
    • 84872198988 scopus 로고    scopus 로고
    • A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas
    • Den RB, Kamrava M, Sheng Z, et al. A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys. 2013;85(2):321-328.
    • (2013) Int J Radiat Oncol Biol Phys , vol.85 , Issue.2 , pp. 321-328
    • Den, R.B.1    Kamrava, M.2    Sheng, Z.3
  • 84
    • 0027322679 scopus 로고
    • Protein kinase C isoenzymes: Divergence in signal transduction?
    • Hug H, Sarre TF. Protein kinase C isoenzymes: divergence in signal transduction? Biochem J. 1993;291(Pt 2):329-343.
    • (1993) Biochem J , vol.291 , Issue.PART 2 , pp. 329-343
    • Hug, H.1    Sarre, T.F.2
  • 85
    • 0034221202 scopus 로고    scopus 로고
    • The role of protein kinase C isoforms in cell proliferation and apoptosis
    • Musashi M, Ota S, Shiroshita N. The role of protein kinase C isoforms in cell proliferation and apoptosis. Int J Hematol. 2000;72(1):12-19.
    • (2000) Int J Hematol , vol.72 , Issue.1 , pp. 12-19
    • Musashi, M.1    Ota, S.2    Shiroshita, N.3
  • 86
    • 0035880256 scopus 로고    scopus 로고
    • Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
    • Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98(2):428-435.
    • (2001) Blood , vol.98 , Issue.2 , pp. 428-435
    • Podar, K.1    Tai, Y.T.2    Davies, F.E.3
  • 87
    • 0033199874 scopus 로고    scopus 로고
    • Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis
    • Yoshiji H, Kuriyama S, Ways DK, et al. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res. 1999;59(17): 4413-4418.
    • (1999) Cancer Res , vol.59 , Issue.17 , pp. 4413-4418
    • Yoshiji, H.1    Kuriyama, S.2    Ways, D.K.3
  • 88
    • 0035657643 scopus 로고    scopus 로고
    • Protein kinase C inhibitors as novel anti-cancer drugs
    • Goekjian PG, Jirousek MR. Protein kinase C inhibitors as novel anti-cancer drugs. Expert Opin Investig Drugs. 2001;10(12):2117-2140.
    • (2001) Expert Opin Investig Drugs , vol.10 , Issue.12 , pp. 2117-2140
    • Goekjian, P.G.1    Jirousek, M.R.2
  • 89
    • 0036137647 scopus 로고    scopus 로고
    • Antiangiogenic effects of a protein kinase Cbeta-selective small molecule
    • Teicher BA, Alvarez E, Menon K, et al. Antiangiogenic effects of a protein kinase Cbeta-selective small molecule. Cancer Chemother Pharmacol. 2002;49(1):69-77.
    • (2002) Cancer Chemother Pharmacol , vol.49 , Issue.1 , pp. 69-77
    • Teicher, B.A.1    Alvarez, E.2    Menon, K.3
  • 90
    • 0442329299 scopus 로고    scopus 로고
    • LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice
    • Keyes KA, Mann L, Sherman M, et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol. 2004;53(2):133-140.
    • (2004) Cancer Chemother Pharmacol , vol.53 , Issue.2 , pp. 133-140
    • Keyes, K.A.1    Mann, L.2    Sherman, M.3
  • 91
    • 23844521568 scopus 로고    scopus 로고
    • The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts
    • Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005;65(16):7462-7469.
    • (2005) Cancer Res , vol.65 , Issue.16 , pp. 7462-7469
    • Graff, J.R.1    McNulty, A.M.2    Hanna, K.R.3
  • 92
    • 77953752349 scopus 로고    scopus 로고
    • Enzastaurin, an inhibitor of PKCbeta, enhances antiangiogenic effects and cytotoxicity of radiation against endothelial cells
    • Spalding AC, Zeitlin BD, Wilder-Romans K, et al. Enzastaurin, an inhibitor of PKCbeta, enhances antiangiogenic effects and cytotoxicity of radiation against endothelial cells. Transl Oncol. 2008;1(4):195-201.
    • (2008) Transl Oncol , vol.1 , Issue.4 , pp. 195-201
    • Spalding, A.C.1    Zeitlin, B.D.2    Wilder-Romans, K.3
  • 93
    • 77955491136 scopus 로고    scopus 로고
    • Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation
    • Willey CD, Xiao D, Tu T, et al. Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation. Int J Radiat Oncol Biol Phys. 2010;77(5):1518-1526.
    • (2010) Int J Radiat Oncol Biol Phys , vol.77 , Issue.5 , pp. 1518-1526
    • Willey, C.D.1    Xiao, D.2    Tu, T.3
  • 94
    • 33847677276 scopus 로고    scopus 로고
    • Synergistic antiglioma activity of radiotherapy and enzastaurin
    • Tabatabai G, Frank B, Wick A, et al. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann Neurol. 2007;61(2):153-161.
    • (2007) Ann Neurol , vol.61 , Issue.2 , pp. 153-161
    • Tabatabai, G.1    Frank, B.2    Wick, A.3
  • 95
    • 77957069911 scopus 로고    scopus 로고
    • Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: A phase I study
    • Butowski N, Chang SM, Lamborn KR, et al. Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro-oncology. 2010;12(6):608-613.
    • (2010) Neuro-oncology , vol.12 , Issue.6 , pp. 608-613
    • Butowski, N.1    Chang, S.M.2    Lamborn, K.R.3
  • 96
    • 84863011588 scopus 로고    scopus 로고
    • Phase II and phar-macogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma
    • Butowski N, Chang SM, Lamborn KR, et al. Phase II and phar-macogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro-oncology. 2011;13(12):1331-1338.
    • (2011) Neuro-oncology , vol.13 , Issue.12 , pp. 1331-1338
    • Butowski, N.1    Chang, S.M.2    Lamborn, K.R.3
  • 97
    • 4544289953 scopus 로고    scopus 로고
    • Phase II study of temozo-lomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme
    • Chang SM, Lamborn KR, Malec M, et al. Phase II study of temozo-lomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2004;60(2): 353-357.
    • (2004) Int J Radiat Oncol Biol Phys , vol.60 , Issue.2 , pp. 353-357
    • Chang, S.M.1    Lamborn, K.R.2    Malec, M.3
  • 98
    • 20144388196 scopus 로고    scopus 로고
    • A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma
    • Butowski N, Prados MD, Lamborn KR, et al. A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Radiat Oncol Biol Phys. 2005;61(5):1454-1459.
    • (2005) Int J Radiat Oncol Biol Phys , vol.61 , Issue.5 , pp. 1454-1459
    • Butowski, N.1    Prados, M.D.2    Lamborn, K.R.3
  • 99
    • 0028911765 scopus 로고
    • Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue
    • Gingras MC, Roussel E, Bruner JM, Branch CD, Moser RP. Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue. J Neuroimmunol. 1995;57(1-2):143-153.
    • (1995) J Neuroimmunol , vol.57 , Issue.1-2 , pp. 143-153
    • Gingras, M.C.1    Roussel, E.2    Bruner, J.M.3    Branch, C.D.4    Moser, R.P.5
  • 100
    • 0029846478 scopus 로고    scopus 로고
    • Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors
    • Gladson CL. Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors. J Neuropathol Exp Neurol. 1996;55(11):1143-1149.
    • (1996) J Neuropathol Exp Neurol , vol.55 , Issue.11 , pp. 1143-1149
    • Gladson, C.L.1
  • 101
    • 0036488589 scopus 로고    scopus 로고
    • Role of integrins in cell invasion and migration
    • Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2(2):91-100.
    • (2002) Nat Rev Cancer , vol.2 , Issue.2 , pp. 91-100
    • Hood, J.D.1    Cheresh, D.A.2
  • 103
    • 36849048720 scopus 로고    scopus 로고
    • Integrins: Signaling, disease, and therapy
    • Huveneers S, Truong H, Danen HJ. Integrins: signaling, disease, and therapy. Int J Radiat Biol. 2007;83(11-12):743-751.
    • (2007) Int J Radiat Biol , vol.83 , Issue.11-12 , pp. 743-751
    • Huveneers, S.1    Truong, H.2    Danen, H.J.3
  • 104
    • 72949119124 scopus 로고    scopus 로고
    • Integrins in cancer: Biological implications and therapeutic opportunities
    • Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9-22.
    • (2010) Nat Rev Cancer , vol.10 , Issue.1 , pp. 9-22
    • Desgrosellier, J.S.1    Cheresh, D.A.2
  • 105
    • 24344434550 scopus 로고    scopus 로고
    • Inhibition of alpha(v) beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy
    • Abdollahi A, Griggs DW, Zieher H, et al. Inhibition of alpha(v) beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res. 2005;11(17):6270-6279.
    • (2005) Clin Cancer Res , vol.11 , Issue.17 , pp. 6270-6279
    • Abdollahi, A.1    Griggs, D.W.2    Zieher, H.3
  • 106
    • 34548545106 scopus 로고    scopus 로고
    • Targeting integrins and PI3K/Akt-mediated signal transduction pathways enhances radiation-induced anti-angiogenesis
    • Ning S, Chen Z, Dirks A, et al. Targeting integrins and PI3K/Akt-mediated signal transduction pathways enhances radiation-induced anti-angiogenesis. Radiat Res. 2007;168(1):125-133.
    • (2007) Radiat Res , vol.168 , Issue.1 , pp. 125-133
    • Ning, S.1    Chen, Z.2    Dirks, A.3
  • 107
    • 44949151575 scopus 로고    scopus 로고
    • Alphavbeta3 and alphav-beta5 integrins control glioma cell response to ionising radiation through ILK and RhoB
    • Monferran S, Skuli N, Delmas C, et al. Alphavbeta3 and alphav-beta5 integrins control glioma cell response to ionising radiation through ILK and RhoB. Int J Cancer. 2008;123(2):357-364.
    • (2008) Int J Cancer , vol.123 , Issue.2 , pp. 357-364
    • Monferran, S.1    Skuli, N.2    Delmas, C.3
  • 108
    • 49849104203 scopus 로고    scopus 로고
    • Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo
    • Ning S, Nemeth JA, Hanson RL, Forsythe K, Knox SJ. Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo. Mol Cancer Ther. 2008;7(6): 1569-1578.
    • (2008) Mol Cancer Ther , vol.7 , Issue.6 , pp. 1569-1578
    • Ning, S.1    Nemeth, J.A.2    Hanson, R.L.3    Forsythe, K.4    Knox, S.J.5
  • 109
    • 77957327440 scopus 로고    scopus 로고
    • Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats
    • Ning S, Tian J, Marshall DJ, Knox SJ. Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res. 2010;70(19):7591-7599.
    • (2010) Cancer Res , vol.70 , Issue.19 , pp. 7591-7599
    • Ning, S.1    Tian, J.2    Marshall, D.J.3    Knox, S.J.4
  • 110
    • 0037186502 scopus 로고    scopus 로고
    • Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins
    • Goodman SL, Hölzemann G, Sulyok GA, Kessler H. Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins. J Med Chem. 2002;45(5):1045-1051.
    • (2002) J Med Chem , vol.45 , Issue.5 , pp. 1045-1051
    • Goodman, S.L.1    Hölzemann, G.2    Sulyok, G.A.3    Kessler, H.4
  • 111
    • 28044458526 scopus 로고    scopus 로고
    • Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist
    • Belvisi L, Riccioni T, Marcellini M, et al. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist. Mol Cancer Ther. 2005;4(11):1670-1680.
    • (2005) Mol Cancer Ther , vol.4 , Issue.11 , pp. 1670-1680
    • Belvisi, L.1    Riccioni, T.2    Marcellini, M.3
  • 112
    • 0033549864 scopus 로고    scopus 로고
    • N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists
    • Dechantsreiter MA, Planker E, Mathä B, et al. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem. 1999;42(16):3033-3040.
    • (1999) J Med Chem , vol.42 , Issue.16 , pp. 3033-3040
    • Dechantsreiter, M.A.1    Planker, E.2    Mathä, B.3
  • 113
    • 84859429437 scopus 로고    scopus 로고
    • Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/ PCF prostate cancer clinical trials consortium
    • Alva A, Slovin S, Daignault S, et al. Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/ PCF prostate cancer clinical trials consortium. Invest New Drugs. 2012;30(2):749-757.
    • (2012) Invest New Drugs , vol.30 , Issue.2 , pp. 749-757
    • Alva, A.1    Slovin, S.2    Daignault, S.3
  • 114
    • 33846604223 scopus 로고    scopus 로고
    • A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unre-sectable pancreatic cancer
    • Friess H, Langrehr JM, Oettle H, et al. A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unre-sectable pancreatic cancer. BMC Cancer. 2006;6:285.
    • (2006) BMC Cancer , vol.6 , pp. 285
    • Friess, H.1    Langrehr, J.M.2    Oettle, H.3
  • 115
    • 79957671402 scopus 로고    scopus 로고
    • Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: Findings of the phase I part
    • Vermorken JB, Guigay J, Mesia R, et al. Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer. 2011;104(11):1691-1696.
    • (2011) Br J Cancer , vol.104 , Issue.11 , pp. 1691-1696
    • Vermorken, J.B.1    Guigay, J.2    Mesia, R.3
  • 116
    • 34249087162 scopus 로고    scopus 로고
    • Phase I and correla-tive biology study of cilengitide in patients with recurrent malignant glioma
    • Nabors LB, Mikkelsen T, Rosenfeld SS, et al. Phase I and correla-tive biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol. 2007;25(13):1651-1657.
    • (2007) J Clin Oncol , vol.25 , Issue.13 , pp. 1651-1657
    • Nabors, L.B.1    Mikkelsen, T.2    Rosenfeld, S.S.3
  • 117
    • 39749191543 scopus 로고    scopus 로고
    • Phase I clinical trial of cilen-gitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012
    • MacDonald TJ, Stewart CF, Kocak M, et al. Phase I clinical trial of cilen-gitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol. 2008;26(6): 919-924.
    • (2008) J Clin Oncol , vol.26 , Issue.6 , pp. 919-924
    • Macdonald, T.J.1    Stewart, C.F.2    Kocak, M.3
  • 118
    • 57149108506 scopus 로고    scopus 로고
    • Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme
    • Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008;26(34):5610-5617.
    • (2008) J Clin Oncol , vol.26 , Issue.34 , pp. 5610-5617
    • Reardon, D.A.1    Fink, K.L.2    Mikkelsen, T.3
  • 119
    • 83055173043 scopus 로고    scopus 로고
    • Cilengitide in patients with recurrent glioblastoma: The results of NABTC 03-02, a phase II trial with measures of treatment delivery
    • Gilbert MR, Kuhn J, Lamborn KR, et al. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol. 2012;106(1): 147-153.
    • (2012) J Neurooncol , vol.106 , Issue.1 , pp. 147-153
    • Gilbert, M.R.1    Kuhn, J.2    Lamborn, K.R.3
  • 120
    • 33748574545 scopus 로고    scopus 로고
    • Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models
    • Albert JM, Cao C, Geng L, Leavitt L, Hallahan DE, Lu B. Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys. 2006;65(5):1536-1543.
    • (2006) Int J Radiat Oncol Biol Phys , vol.65 , Issue.5 , pp. 1536-1543
    • Albert, J.M.1    Cao, C.2    Geng, L.3    Leavitt, L.4    Hallahan, D.E.5    Lu, B.6
  • 121
    • 64249086909 scopus 로고    scopus 로고
    • Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency
    • Mikkelsen T, Brodie C, Finniss S, et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer. 2009;124(11):2719-2727.
    • (2009) Int J Cancer , vol.124 , Issue.11 , pp. 2719-2727
    • Mikkelsen, T.1    Brodie, C.2    Finniss, S.3
  • 122
    • 84896817005 scopus 로고    scopus 로고
    • Bethesda, MD: National Institutes of Health; Available from, Accessed May
    • ClinicalTrials.gov [homepage on the Internet]. ClinicalTrials.gov: A service of the US National Institutes of Health. Bethesda, MD: National Institutes of Health; Available from: http://www.clinicaltrials.gov. Accessed May 2013.
    • (2013) ClinicalTrials.gov [homepage On the Internet]
  • 123
    • 0034773992 scopus 로고    scopus 로고
    • The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities
    • Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001; 37 Suppl 4:S3-S8.
    • (2001) Eur J Cancer , vol.37 , Issue.4 SUPPL.
    • Yarden, Y.1
  • 124
    • 0028955388 scopus 로고
    • Epidermal growth factor-related peptides and their receptors in human malignancies
    • Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19(3):183-232.
    • (1995) Crit Rev Oncol Hematol , vol.19 , Issue.3 , pp. 183-232
    • Salomon, D.S.1    Brandt, R.2    Ciardiello, F.3    Normanno, N.4
  • 125
    • 0022372783 scopus 로고
    • Amplification and over-expression of the EGF receptor gene in primary human glioblastomas
    • Libermann TA, Nusbaum HR, Razon N, et al. Amplification and over-expression of the EGF receptor gene in primary human glioblastomas. J Cell Sci Suppl. 1985;3:161-172.
    • (1985) J Cell Sci Suppl , vol.3 , pp. 161-172
    • Libermann, T.A.1    Nusbaum, H.R.2    Razon, N.3
  • 126
    • 0023429079 scopus 로고
    • Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification
    • Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A. 1987;84(19):6899-6903.
    • (1987) Proc Natl Acad Sci U S A , vol.84 , Issue.19 , pp. 6899-6903
    • Wong, A.J.1    Bigner, S.H.2    Bigner, D.D.3    Kinzler, K.W.4    Hamilton, S.R.5    Vogelstein, B.6
  • 128
    • 0035479296 scopus 로고    scopus 로고
    • EGFR overexpression and radiation response in glioblastoma multiforme
    • Barker FG Jr, Simmons ML, Chang SM, et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001;51(2):410-418.
    • (2001) Int J Radiat Oncol Biol Phys , vol.51 , Issue.2 , pp. 410-418
    • Barker Jr., F.G.1    Simmons, M.L.2    Chang, S.M.3
  • 129
    • 14444288522 scopus 로고    scopus 로고
    • The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling
    • Huang HS, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem. 1997;272(5):2927-2935.
    • (1997) J Biol Chem , vol.272 , Issue.5 , pp. 2927-2935
    • Huang, H.S.1    Nagane, M.2    Klingbeil, C.K.3
  • 130
    • 14644412873 scopus 로고    scopus 로고
    • Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients
    • Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005;11(4):1462-1466.
    • (2005) Clin Cancer Res , vol.11 , Issue.4 , pp. 1462-1466
    • Heimberger, A.B.1    Hlatky, R.2    Suki, D.3
  • 131
    • 0032763824 scopus 로고    scopus 로고
    • Expression of acti-vated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multi-forme specimens
    • Feldkamp MM, Lala P, Lau N, Roncari L, Guha A. Expression of acti-vated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multi-forme specimens. Neurosurgery. 1999;45(6):1442-1453.
    • (1999) Neurosurgery , vol.45 , Issue.6 , pp. 1442-1453
    • Feldkamp, M.M.1    Lala, P.2    Lau, N.3    Roncari, L.4    Guha, A.5
  • 132
    • 77956344241 scopus 로고    scopus 로고
    • The effect of epidermal growth factor receptor variant III on glioma cell migration by stimulating ERK phosphorylation through the focal adhesion kinase signaling pathway
    • Liu M, Yang Y, Wang C, et al. The effect of epidermal growth factor receptor variant III on glioma cell migration by stimulating ERK phosphorylation through the focal adhesion kinase signaling pathway. Arch Biochem Biophys. 2010;502(2):89-95.
    • (2010) Arch Biochem Biophys , vol.502 , Issue.2 , pp. 89-95
    • Liu, M.1    Yang, Y.2    Wang, C.3
  • 133
    • 70149112112 scopus 로고    scopus 로고
    • Fyn and SRC are effectors of onco-genic epidermal growth factor receptor signaling in glioblastoma patients
    • Lu KV, Zhu S, Cvrljevic A, et al. Fyn and SRC are effectors of onco-genic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res. 2009;69(17):6889-6898.
    • (2009) Cancer Res , vol.69 , Issue.17 , pp. 6889-6898
    • Lu, K.V.1    Zhu, S.2    Cvrljevic, A.3
  • 134
    • 84866061138 scopus 로고    scopus 로고
    • EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway
    • Bonavia R, Inda MM, Vandenberg S, et al. EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway. Oncogene. 2012;31(36):4054-4066.
    • (2012) Oncogene , vol.31 , Issue.36 , pp. 4054-4066
    • Bonavia, R.1    Inda, M.M.2    Vandenberg, S.3
  • 135
    • 0036141447 scopus 로고    scopus 로고
    • Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phos-phoinositide 3-kinase signaling
    • Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phos-phoinositide 3-kinase signaling. Cancer Res. 2002;62(1): 200-207.
    • (2002) Cancer Res , vol.62 , Issue.1 , pp. 200-207
    • Chakravarti, A.1    Loeffler, J.S.2    Dyson, N.J.3
  • 136
    • 33746485766 scopus 로고    scopus 로고
    • Epidermal growth factor receptor targeting in cancer
    • Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33(4):369-385.
    • (2006) Semin Oncol , vol.33 , Issue.4 , pp. 369-385
    • Mendelsohn, J.1    Baselga, J.2
  • 137
    • 56249109644 scopus 로고    scopus 로고
    • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial
    • Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809-1818.
    • (2008) Lancet , vol.372 , Issue.9652 , pp. 1809-1818
    • Kim, E.S.1    Hirsh, V.2    Mok, T.3
  • 138
    • 77953541527 scopus 로고    scopus 로고
    • SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study
    • Cappuzzo F, Ciuleanu T, Stelmakh L, et al; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(6):521-529.
    • (2010) Lancet Oncol , vol.11 , Issue.6 , pp. 521-529
    • Cappuzzo, F.1    Ciuleanu, T.2    Stelmakh, L.3
  • 139
    • 84862007544 scopus 로고    scopus 로고
    • Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: A phase III trial of gemcitabine plus erlotinib or placebo
    • Vickers MM, Powell ED, Asmis TR, et al. Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. Eur J Cancer. 2012;48(10):1434-1442.
    • (2012) Eur J Cancer , vol.48 , Issue.10 , pp. 1434-1442
    • Vickers, M.M.1    Powell, E.D.2    Asmis, T.R.3
  • 140
    • 62449150719 scopus 로고    scopus 로고
    • Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
    • van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009;27(8):1268-1274.
    • (2009) J Clin Oncol , vol.27 , Issue.8 , pp. 1268-1274
    • van den Bent, M.J.1    Brandes, A.A.2    Rampling, R.3
  • 141
    • 1842500007 scopus 로고    scopus 로고
    • Phase II trial of gefitinib in recurrent glioblastoma
    • Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004;22(1):133-142.
    • (2004) J Clin Oncol , vol.22 , Issue.1 , pp. 133-142
    • Rich, J.N.1    Reardon, D.A.2    Peery, T.3
  • 142
    • 0036795061 scopus 로고    scopus 로고
    • Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa)
    • Bianco C, Tortora G, Bianco R, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res. 2002;8(10):3250-3258.
    • (2002) Clin Cancer Res , vol.8 , Issue.10 , pp. 3250-3258
    • Bianco, C.1    Tortora, G.2    Bianco, R.3
  • 143
    • 17144371349 scopus 로고    scopus 로고
    • Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)
    • Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005;65(8):3328-3335.
    • (2005) Cancer Res , vol.65 , Issue.8 , pp. 3328-3335
    • Chinnaiyan, P.1    Huang, S.2    Vallabhaneni, G.3
  • 144
    • 33646228168 scopus 로고    scopus 로고
    • Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response
    • Sarkaria JN, Carlson BL, Schroeder MA, et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res. 2006;12(7 Pt 1):2264-2271.
    • (2006) Clin Cancer Res , vol.12 , Issue.7 PART 1 , pp. 2264-2271
    • Sarkaria, J.N.1    Carlson, B.L.2    Schroeder, M.A.3
  • 145
    • 1242270613 scopus 로고    scopus 로고
    • The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: A review of preclinical and correlative clinical data
    • Chakravarti A, Dicker A, Mehta M. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J Radiat Oncol Biol Phys. 2004;58(3):927-931.
    • (2004) Int J Radiat Oncol Biol Phys , vol.58 , Issue.3 , pp. 927-931
    • Chakravarti, A.1    Dicker, A.2    Mehta, M.3
  • 146
    • 0036638837 scopus 로고    scopus 로고
    • Epidermal growth factor receptor modulation of radiation response: Preclinical and clinical development
    • Harari PM, Huang SM. Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development. Semin Radiat Oncol. 2002;12(3 Suppl 2):21-26.
    • (2002) Semin Radiat Oncol , vol.12 , Issue.3 SUPPL. 2 , pp. 21-26
    • Harari, P.M.1    Huang, S.M.2
  • 147
    • 33745183568 scopus 로고    scopus 로고
    • North Central Cancer Treatment Group. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: Results of North Central Can-cer Treatment Group protocol N0177
    • Krishnan S, Brown PD, Ballman KV, et al; North Central Cancer Treatment Group. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Can-cer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys. 2006;65(4):1192-1199.
    • (2006) Int J Radiat Oncol Biol Phys , vol.65 , Issue.4 , pp. 1192-1199
    • Krishnan, S.1    Brown, P.D.2    Ballman, K.V.3
  • 148
    • 59449092893 scopus 로고    scopus 로고
    • Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma
    • Broniscer A, Baker SJ, Stewart CF, et al. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin Cancer Res. 2009;15(2):701-707.
    • (2009) Clin Cancer Res , vol.15 , Issue.2 , pp. 701-707
    • Broniscer, A.1    Baker, S.J.2    Stewart, C.F.3
  • 149
    • 57149118473 scopus 로고    scopus 로고
    • North Central Cancer Treatment Group Study N0177. Phase I/II trial of erlotinib and temo-zolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177
    • Brown PD, Krishnan S, Sarkaria JN, et al; North Central Cancer Treatment Group Study N0177. Phase I/II trial of erlotinib and temo-zolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol. 2008;26(34):5603-5609.
    • (2008) J Clin Oncol , vol.26 , Issue.34 , pp. 5603-5609
    • Brown, P.D.1    Krishnan, S.2    Sarkaria, J.N.3
  • 150
    • 39749192759 scopus 로고    scopus 로고
    • A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas
    • Schwer AL, Damek DM, Kavanagh BD, et al. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2008;70(4):993-1001.
    • (2008) Int J Radiat Oncol Biol Phys , vol.70 , Issue.4 , pp. 993-1001
    • Schwer, A.L.1    Damek, D.M.2    Kavanagh, B.D.3
  • 151
    • 78649632132 scopus 로고    scopus 로고
    • A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas
    • Geyer JR, Stewart CF, Kocak M, et al. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer. 2010;46(18):3287-3293.
    • (2010) Eur J Cancer , vol.46 , Issue.18 , pp. 3287-3293
    • Geyer, J.R.1    Stewart, C.F.2    Kocak, M.3
  • 152
    • 79955751294 scopus 로고    scopus 로고
    • A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: A report from the Pediatric Brain Tumor Consortium
    • Pollack IF, Stewart CF, Kocak M, et al. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro-oncology. 2011;13(3):290-297.
    • (2011) Neuro-oncology , vol.13 , Issue.3 , pp. 290-297
    • Pollack, I.F.1    Stewart, C.F.2    Kocak, M.3
  • 153
    • 84875239034 scopus 로고    scopus 로고
    • RTOG 0211: A phase 1/2 study of radiation therapy with concurrent gefitinib for newly diag-nosed glioblastoma patients
    • Chakravarti A, Wang M, Robins HI, et al. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diag-nosed glioblastoma patients. Int J Radiat Oncol Biol Phys. 2013;85(5): 1206-1211.
    • (2013) Int J Radiat Oncol Biol Phys , vol.85 , Issue.5 , pp. 1206-1211
    • Chakravarti, A.1    Wang, M.2    Robins, H.I.3
  • 154
    • 0033429554 scopus 로고    scopus 로고
    • Mammalian target of rapamycin is a direct target for protein kinase B: Identification of a convergence point for opposing effects of insu-lin and amino-acid deficiency on protein translation
    • Navé BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insu-lin and amino-acid deficiency on protein translation. Biochem J. 1999;344 Pt 2:427-431.
    • Biochem J. 1999;344 Pt , vol.2 , pp. 427-431
    • Navé, B.T.1    Ouwens, M.2    Withers, D.J.3    Alessi, D.R.4    Shepherd, P.R.5
  • 155
    • 0037097863 scopus 로고    scopus 로고
    • Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E
    • Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002;16(12):1472-1487.
    • (2002) Genes Dev , vol.16 , Issue.12 , pp. 1472-1487
    • Fingar, D.C.1    Salama, S.2    Tsou, C.3    Harlow, E.4    Blenis, J.5
  • 156
    • 77956236877 scopus 로고    scopus 로고
    • PI(3)king apart PTEN's role in cancer
    • Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res. 2010;16(17):4325-4330.
    • (2010) Clin Cancer Res , vol.16 , Issue.17 , pp. 4325-4330
    • Zhang, S.1    Yu, D.2
  • 157
    • 84877244768 scopus 로고    scopus 로고
    • Targeting the PI3K-AKT-motor signaling network in cancer
    • Khan KH, Yap TA, Yan L, Cunningham D. Targeting the PI3K-AKT-motor signaling network in cancer. Chim J cancer. 2013;32(5): 253-265.
    • (2013) Chim J Cancer , vol.32 , Issue.5 , pp. 253-265
    • Khan, K.H.1    Yap, T.A.2    Yan, L.3    Cunningham, D.4
  • 158
    • 84861229141 scopus 로고    scopus 로고
    • Molecolar therapies for tuberous selerosis and neurofibromatosis
    • Franz DN, Weiss BD. Molecolar therapies for tuberous selerosis and neurofibromatosis. Cover Neurol Neurosci Rep. 2012; 12(3): 294-302.
    • (2012) Cover Neurol Neurosci Rep , vol.12 , Issue.3 , pp. 294-302
    • Franz, D.N.1    Weiss, B.D.2
  • 159
    • 0037115523 scopus 로고    scopus 로고
    • Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy
    • Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res. 2002;62(24):7291-7297.
    • (2002) Cancer Res , vol.62 , Issue.24 , pp. 7291-7297
    • Eshleman, J.S.1    Carlson, B.L.2    Mladek, A.C.3    Kastner, B.D.4    Shide, K.L.5    Sarkaria, J.N.6
  • 160
    • 79953217107 scopus 로고    scopus 로고
    • Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy
    • Anandharaj A, Cinghu S, Park WY. Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy. Acta Biochim Biophys Sin (Shanghai). 2011;43(4): 292-300.
    • (2011) Acta Biochim Biophys Sin (Shanghai) , vol.43 , Issue.4 , pp. 292-300
    • Anandharaj, A.1    Cinghu, S.2    Park, W.Y.3
  • 161
    • 33845974091 scopus 로고    scopus 로고
    • Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling
    • Kim KW, Mutter RW, Cao C, et al. Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling. J Biol Chem. 2006;281(48):36883-36890.
    • (2006) J Biol Chem , vol.281 , Issue.48 , pp. 36883-36890
    • Kim, K.W.1    Mutter, R.W.2    Cao, C.3
  • 162
    • 24644447853 scopus 로고    scopus 로고
    • Enhanced radiation damage of tumor vasculature by mTOR inhibitors
    • Shinohara ET, Cao C, Niermann K, et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene. 2005;24(35):5414-5422.
    • (2005) Oncogene , vol.24 , Issue.35 , pp. 5414-5422
    • Shinohara, E.T.1    Cao, C.2    Niermann, K.3
  • 163
    • 78349245231 scopus 로고    scopus 로고
    • Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks
    • Sarkaria JN, Galanis E, Wu W, et al. Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clin Cancer Res. 2010;16(22):5573-5580.
    • (2010) Clin Cancer Res , vol.16 , Issue.22 , pp. 5573-5580
    • Sarkaria, J.N.1    Galanis, E.2    Wu, W.3
  • 164
    • 80052820448 scopus 로고    scopus 로고
    • North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diag-nosed glioblastoma multiforme
    • Sarkaria JN, Galanis E, Wu W, et al. North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diag-nosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011;81(2):468-475.
    • (2011) Int J Radiat Oncol Biol Phys , vol.81 , Issue.2 , pp. 468-475
    • Sarkaria, J.N.1    Galanis, E.2    Wu, W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.